Cambridge Investment Research Advisors’s Pacira BioSciences PCRX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.25M	Buy	127,996 +5,234	+4%	+$124K	0.01%	1322
2026 Q1	$2.77M	Buy	122,762 +17,617	+17%	+$392K	0.01%	1341
2025 Q4	$2.72M	Buy	+105,145	New	+$2.5M	0.01%	1291
2020 Q3	–	Sell	-4,420	Closed	-$232K	–	2579
2020 Q2	$232K	Sell	4,420 -3,608	-45%	-$151K	﹤0.01%	2075
2020 Q1	$269K	Buy	8,028 +2,450	+44%	+$102K	﹤0.01%	1737
2019 Q4	$253K	Sell	5,578 -1,026	-16%	-$43.6K	﹤0.01%	2024
2019 Q3	$251K	Buy	6,604 +185	+3%	+$7.38K	﹤0.01%	1953
2019 Q2	$279K	Hold	6,419	–	–	﹤0.01%	1781
2019 Q1	$244K	Buy	6,419 +447	+7%	+$17.4K	﹤0.01%	1941
2018 Q4	$257K	Sell	5,972 -651	-10%	-$30.4K	﹤0.01%	1760
2018 Q3	$326K	Buy	+6,623	New	+$286K	﹤0.01%	1742

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors's PCRX Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Pacira BioSciences (PCRX) stake by 4.3% in Q2 2026, buying an estimated $124K and bringing the position to 127,996 shares worth $3.25M. The position accounts for 0.01% of the portfolio, ranked #1322.

Cambridge Investment Research Advisors first reported a position in PCRX in Q3 2018 and has held it in 11 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Cambridge Investment Research Advisors held 127,996 shares of Pacira BioSciences worth $3.25M as of Q2 2026.
Cambridge Investment Research Advisors bought 5,234 Pacira BioSciences shares in Q2 2026, an estimated $124K.
Pacira BioSciences made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1322 holding.
Cambridge Investment Research Advisors first reported a position in Pacira BioSciences in Q3 2018 and has held it in 11 quarters since.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.